 BOSTON, Aug. 04, 2021 GLOBE NEWSWIRE -- Paratek Pharmaceuticals, Inc. Nasdaq: PRTK, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for civilian, government and military use, today announced that the Companys novel, once-daily oral and intravenous antibiotic NUZYRA omadacycline has recently been added to the Center for Disease Control and Preventions CDC updated report, Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response. NUZYRA was added as an alternative agent for the treatment, pre-exposure prophylaxis, and postexposure prophylaxis of primary bubonic and pharyngeal plague infections in adults 18 years of age and over. 